- U.S. revenue increased 24% in the third quarter of 2016 compared to the third quarter of 2015.
- International revenue increased 11% in the third quarter of 2016 compared to the third quarter of 2015.
- Closing of $26.5 million public offering in 3 rd quarter and restructuring of Alimera's existing loan facility in October provides working capital to drive towards profitability.
- First shipments to the Middle East market.
ATLANTA, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the quarter ended September 30, 2016. Highlights